A Preliminary Study of the Value of Plasma microRNA-193b and Soluble Urokinase-Type Plasminogen Activator Receptor in Identifying Patients with Early-Stage Colorectal Cancer and.

Related Articles

A Preliminary Study of the Value of Plasma microRNA-193b and Soluble Urokinase-Type Plasminogen Activator Receptor in Identifying Patients with Early-Stage Colorectal Cancer and.

Clin Lab. 2017 Nov 01;63(11):1949-1953

Authors: Liu KL, Luo JL, Wu J, Wang YD, Fan HJ

Abstract
BACKGROUND: Early detection and management of colorectal cancer (CRC) and colorectal adenoma (CRA) reduces the mortality and morbidity of CRC, but there is a lack of ideal circulation biomarkers.
METHODS: A total of 80 patients with early-stage CRC and CRA and 30 healthy controls were included in this preliminary study. Plasma samples were collected before colonoscopy and prepared for measurement of microRNA193b and soluble uPAR.
RESULTS: Plasma level of miR-193b was decreased through the normal-adenoma-carcinoma sequence with no significant difference between patients with CRC and advanced CRA. The AUC of ROC curve evaluating the value of miR-193b in discriminating patients with early stage CRC or advanced CRA from patients with non-advanced CRA or normal control subjects was 0.849 (95% CI 0.773 - 0.923, p < 0.001). Significant alteration of plasma suPAR is only observed in CRC group (p < 0.001).
CONCLUSIONS: Plasma miR-193b may be a novel candidate biomarker for screening patients with early-stage CRC and advanced CRA.

PMID: 29226653 [PubMed - in process]

http://ift.tt/2iXZfHJ